Every benefits review published last year asked the same questions about telemedicine platforms: Does it integrate with your EHR? What's the wait time? How much per employee per month?
Here's what none of them asked: Who actually profits when your employees use it-and who loses?
After two decades in benefits systems, I can tell you the dirty secret about "free" telemedicine bundled into your health plan: it's often designed to increase total system costs, not reduce them.
The Business Model Hidden in Plain Sight
Most major carriers now bundle telemedicine as a "value-add" benefit. Zero copay for employees, $2-4 per employee per month for you. Reviews praised this as democratizing healthcare access.
They missed the business model entirely.
Here's how bundled telemedicine platforms actually make money:
Step 1: Virtual visit generates a prescription (happens in 70%+ of acute care telemedicine encounters)
Step 2: Prescription routes through the carrier's affiliated PBM
Step 3: PBM captures spread pricing, rebate retention, and formulary steering revenue
Step 4: Platform receives referral fees or data-sharing compensation
The telemedicine visit is loss leader marketing for pharmacy profit extraction.
The Math Nobody Showed You
Let me walk you through a real scenario:
Traditional pharmacy route:
- Employee with sinus infection gets azithromycin prescription
- Wholesale cost: $4
- Employee copay: $10
- You pay: $15
- Total: $25
Telemedicine-generated route through affiliated PBM:
- Same employee, same sinus infection, same antibiotic
- Employee copay: $10
- PBM bills you: $47 (spread pricing)
- Platform receives $8 referral fee
- Total: $65
Your $2 PEPM "savings" just cost you an extra $40 in hidden pharmacy spend.
Scale this across 500 employees with 15% monthly telemedicine utilization, and your "free" benefit just added $36,000 to your annual costs.
The Data Integration You Didn't Agree To
What Reviews Celebrated
Every review last year praised platforms with "seamless EHR integration" and "care coordination features."
What's Actually Happening
This integration often includes contractual data-sharing clauses that:
- Feed utilization patterns back to carriers for future underwriting
- Identify high-cost members for "care management programs" (read: potential denials)
- Generate "care gap" alerts that push employees toward higher-cost specialty referrals within the carrier's network
Real example: A 300-employee manufacturer saw telemedicine utilization jump from 8% to 23% after a platform upgrade. Review sites praised this as "improved engagement."
Their renewal came in 18% higher.
The platform had identified 47 employees with chronic condition indicators and automatically enrolled them in a "diabetes management program" that generated $127,000 in additional claims through mandatory CGM devices and specialty pharmacy routing.
The platform worked perfectly. Just not for the employer.
The Mental Health Mirage
Nearly every review highlighted expanded mental health access as a major win: licensed therapist visits, psychiatry consultations, 24/7 crisis support.
The Question Nobody Asked
What percentage of mental health telemedicine visits resulted in prescription medication in your population?
If you don't know this number, your platform is hiding it from you.
Industry data suggests 60-75% of virtual psychiatry visits generate a prescription-often brand-name medications with significant PBM profit margins. The fastest-growing category? ADHD medications for adults, averaging $150-400 monthly for brand versions versus $15-30 for generics.
The Incentive Misalignment
- Platform success metric: Visit completion rate
- Provider compensation: Fee-per-visit (productivity model)
- PBM profit: Prescription generation and brand favoritism
- Your goal: Improved mental health outcomes at controlled costs
Only one party in this chain is measured on actual health improvement.
A recent analysis I conducted showed employees using "free" mental health telemedicine had:
- 34% higher psychotropic medication costs
- 19% lower therapy attendance after initial prescription
- No measurable difference in depression scores after 6 months
The platform reported this as a success. The employer saw $89,000 in medication spend with no outcome improvement.
What Reviews Should Have Asked
Critical Question #1: Who Owns the Pharmacy Route?
If your telemedicine platform is bundled through your carrier or has "preferred pharmacy partnerships," you have a conflict of interest baked into every prescription.
Demand in writing:
- Full PBM-platform relationship disclosure
- Average prescription generation rate by visit type
- Spread pricing transparency on telemedicine-originated scripts
- Contractual right to route prescriptions through your own PBM
Critical Question #2: What Happens to Your Data?
Every platform collects chief complaints, diagnostic impressions, prescription history, utilization patterns, and biometric data.
Require contractual protection for:
- Data ownership rights
- Prohibition on sharing with underwriters
- Limits on automatic care management enrollment
- Annual data portability rights
If the contract says data is used for "quality improvement" without defining that term in your favor, you're being mined.
Critical Question #3: What's the Total Episode Cost?
Telemedicine visits trigger downstream expenses:
- Referrals (often in-network only, limiting price competition)
- Diagnostic testing (where does the platform steer these orders?)
- Prescription refills (locked into 90-day mail-order?)
- Follow-up visits (virtual or pushed to higher-cost urgent care?)
Example:
Platform A: $0 copay, $3 PEPM. Average sinus infection visit generates $220 in downstream costs.
Platform B: $20 copay, $0 PEPM. Same condition generates $45 in downstream costs.
Every review last year ranked Platform A higher. Every sophisticated CFO should choose Platform B.
The Real Problem: Utilization Economics vs. Prevention Economics
Every telemedicine review last year operated under utilization economics-the assumption that more access equals better outcomes equals lower costs.
This is the same failed logic that gave us:
- Sky-high insurance premiums (more covered services = higher costs)
- PBM profit extraction (more prescriptions = more rebates)
- Wellness program waste (more screenings = no health improvement)
The truth: More prevention reduces the need for acute visits, which lowers costs and enables wealth building.
Telemedicine is valuable only when it prevents the need for future telemedicine.
A platform that treats a sinus infection is processing an expensive transaction.
A platform that identifies allergic rhinitis patterns, connects the employee to appropriate long-term management, and reduces future acute infections by 60%? That's value.
But you can't see that value in reviews focused on "wait times" and "user satisfaction scores."
How WellthCare Does It Differently
At WellthCare, we don't bundle telemedicine as a utilization driver. We integrate preventive care access as part of our Health-to-Wealth Operating System:
Prevention First: Employees earn Store dollars for completing preventive actions that avoid acute telemedicine visits. The best visit is the one that never happens.
Transparent Pharmacy Routing: When prescriptions are needed, routing is transparent. PBM savings flow back to employee Pension accounts, not hidden intermediaries.
Data Builds Wealth, Not Risk Profiles: Healthcare data triggers Pension contributions and Store rewards-not premium increases or automatic enrollment in high-cost programs.
Aligned Incentives: The best clinical decision is also the best financial decision for employees, employers, and providers. Everyone wins when employees stay healthy.
We measure success by total cost of care reduction and outcome improvement, not visit volume or engagement metrics.
Your Action Plan
Audit Your Current Contract
Request 24 months of data broken down by:
- Condition type
- Prescription generation rates
- Downstream referrals
- Total episode costs (not just visit fees)
Calculate your true PEPM cost including pharmacy and referral expenses.
Demand Contractual Protection
Before signing or renewing, require:
- Prescription Transparency: Monthly reporting of generation rates, pharmacy costs, and all PBM/pharmacy relationships
- Data Quarantine: Explicit prohibition on sharing utilization data with underwriters or auto-enrolling employees in carrier programs
- Total Cost Measurement: Platform reports downstream costs for 90 days post-visit, with performance penalties if episode costs exceed benchmarks
- Incentive Disclosure: How are providers compensated? What partnerships generate platform revenue? Who owns preferred referral networks?
Track the Right Metrics
Monitor monthly:
- Prescription generation rate by visit type
- Average pharmacy cost per telemedicine visit (full PBM cost, not copay)
- Referral rate to specialists
- Total cost per episode by condition
- Changes in urgent care/ER utilization
Red flags:
- Prescription rates above 70% for acute conditions
- High referral rates to high-cost specialists
- Rising pharmacy costs concurrent with rising telemedicine use
- Increasing visit volume without corresponding decrease in other utilization
The Bottom Line
The real story of telemedicine last year wasn't about app interfaces or wait times.
It was about an entire industry-analysts, brokers, employers-asking the wrong questions because they didn't understand the incentive architecture.
Telemedicine platforms aren't neutral tools. They're economic actors with business models that often directly conflict with your cost-containment goals.
Stop evaluating telemedicine as a benefit feature and start evaluating it as a risk management tool.
The right platform should:
- Reduce your total claims spend
- Lower your future underwriting risk
- Improve employee health outcomes measurably
- Increase your negotiating leverage
Until we start evaluating based on total system cost, outcome improvement, and incentive alignment, we'll keep celebrating innovations that quietly extract wealth while claiming to build health.
The platform isn't the problem. The system that rewards utilization over prevention is.
And until that changes, every review will miss what actually matters: Who profits when your employees get sick-and who loses when they get well?
Ready to explore a benefits system where healthcare actually builds employee wealth instead of extracting it? Learn how WellthCare's Health-to-Wealth Operating System aligns incentives across preventive care, pharmacy, and retirement-with no rip-and-replace disruption.
Have you tracked total episode costs for your telemedicine platform, or just per-visit fees? What hidden costs have you discovered? Share your experience in the comments.